Skip to main content

Table 2 Comparison of baseline characteristics between train set and test set*

From: A clinical data-driven machine learning approach for predicting the effectiveness of piperacillin-tazobactam in treating lower respiratory tract infections

Variable

Overall (n = 1314)

Train set (n = 919)

Test set(n = 395)

P value

Age

74.00 (66.00–82.00)

74.00 (66.00–81.00)

75.00 (65.00–82.00)

0.600

EGFR

87.83 (72.15–97.14)

87.82 (71.23–97.12)

87.90 (72.80-97.21)

0.914

Weight

60.00 (53.00–70.00)

60.00 (52.75-70.00)

60.00 (53.30–70.00)

0.851

BUN

6.10 (4.80–7.90)

6.00 (4.80–7.80)

6.30 (4.90–8.20)

0.129

ALB

38.00 (35.30–40.60)

37.90 (35.15–40.65)

38.20 (35.50–40.60)

0.307

LYM

1.15 (0.74–1.61)

1.14 (0.73–1.62)

1.17 (0.76–1.58)

0.734

PCT

0.10 (0.07–0.19)

0.10 (0.07–0.19)

0.10 (0.08–0.19)

0.506

WBC

7.51 (5.75–10.20)

7.59 (5.87–10.38)

7.39 (5.60–9.99)

0.126

CRP

10.27 (1.03–51.67)

10.36 (0.91–51.27)

10.19 (1.45–52.16)

0.457

DD

0.60 (0.32–1.23)

0.61 (0.32–1.25)

0.58 (0.32–1.21)

0.650

NLR

0.75 (0.66–0.83)

0.76 (0.66–0.83)

0.74 (0.65–0.83)

0.348

Sex

863 (65.7%)

603 (65.6%)

260 (65.8%)

0.992

Temp

302 (23.0%)

211 (23.0%)

91 (23.0%)

1.000

RF

286 (21.8%)

208 (22.6%)

78 (19.7%)

0.276

RH

215 (16.4%)

147 (16.0%)

68 (17.2%)

0.641

DM

226 (17.2%)

164 (17.8%)

62 (15.7%)

0.386

CA

213 (16.2%)

156 (17.0%)

57 (14.4%)

0.286

COPD

735 (55.9%)

515 (56.0%)

220 (55.7%)

0.957

BE

242 (18.4%)

170 (18.5%)

72 (18.2%)

0.969

ILD

104 (7.9%)

74 (8.1%)

30 (7.6%)

0.865

CVD

508 (38.7%)

367 (39.9%)

141 (35.7%)

0.166

HF

576 (43.8%)

403 (43.9%)

173 (43.8%)

1.000

OPTH

961 (73.1%)

663 (72.1%)

298 (75.4%)

0.242

PIPD

974 (74.1%)

690 (75.1%)

284 (71.9%)

0.255

Ery

351 (26.7%)

246 (26.8%)

105 (26.6%)

0.999

NXC

192 (14.6%)

142 (15.5%)

50 (12.7%)

0.219

Result

319(24.3%)

214 (23.3%)

105 (26.6%)

0.227

  1. *See Table 1 for full feature names